Horumar cilmi-baaris ah oo ku saabsan isku-darka enzymatic ee horudhacyada suurtagalka ah ee Clenbuterol iyadoo lala kaashanayo Jaamacadda Sayniska iyo Teknolojiyadda ee Norway iyo Shangke Biomedical

Clenbuterol, waa β2-adrenergic agonist (β2-adrenergic agonist), oo la mid ah ephedrine (Ephedrine), waxaa badanaa loo isticmaalaa kiliinikada si loogu daaweeyo cudurka sambabada ee joogtada ah (COPD). Waxaa sidoo kale loo isticmaalaa bronchodilator si loo yareeyo sii xumaanshaha neefta. Horraantii 1980-meeyadii, shirkadda Mareykanka ee Cyanamid ayaa si kama' ah u ogaatay inay leedahay saameyn cad oo kor u qaadida koritaanka, hagaajinta heerka hilibka caatada ah iyo yareynta dufanka, sidaa darteed waxaa loo isticmaalay clenbuterol xannaanada xoolaha. Si kastaba ha ahaatee, sababtoo ah waxyeellooyinkeeda, Bulshada Yurub waxay mamnuucday isticmaalka clenbuterol sidii wax lagu daro quudinta tan iyo Janaayo 1, 1988. Waxaa mamnuucday FDA sanadkii 1991. Sannadkii 1997, Wasaaradda Beeraha ee Jamhuuriyadda Dadka Shiinaha ayaa si adag u mamnuucday isticmaalka hoormoonada beta-adrenergic ee wax soo saarka quudinta iyo xannaanada xoolaha, Clenbuterol hydrochloride-na waxay gashay kaalinta koowaad.

Si kastaba ha ahaatee, Clenbuterol-ka racemic ayaa dhawaan la muujiyay inuu yareeyo khatarta cudurka Parkinson. Si loo xaqiijiyo isomer-yada (ama labadaba) ee soo saara saameyntan, Clenbuterol enantiomer-ka saafiga ah wuxuu u baahan yahay in si gaar ah loo barto.